NCT04822961View on ClinicalTrials.gov

Senaparib in mCRPC Patients With Homologous Recombination Repair Gene Alterations After Docetaxel Treatment

PHASE2UnknownINTERVENTIONAL
Enrollment

285

Participants

Timeline

Start Date

December 31, 2021

Primary Completion Date

May 31, 2024

Study Completion Date

August 31, 2024

Conditions
mCRPC
Interventions
DRUG

Placebo

Senaparib-matched placebo capsules

DRUG

Senaparib

20 mg capsules

Trial Locations (6)

13905

Our lady of Lourdes Urology, Binghamton

Unknown

Princess Alexandra Hospital, Brisbane

Cabrini Hospital, Melbourne

Macquarie University Hospital, Sydney

John Flynn Hospital, Tugun

IMPACT Therapeutics Inc., Shanghai

Sponsors
All Listed Sponsors
lead

Impact Therapeutics, Inc.

INDUSTRY